1. Ho Y-F*, Hsieh L-L, Lu W-C, Hu F-C, Hale KM, Lee S-J, Lin F-J.. Appropriateness of ambulatory prescriptions in Taiwan: translating claims data into initiatives. Int J Clin Pharm 2012; 34:72-80(SCI)
2. Ho Y-F, Lin J-T, Wu C-Y. Oral bisphosphonates and risk of esophageal cancer: a dose-intensity analysis in a nationwide population. Cancer Epidemiol Biomarkers Prev 2012; 21:993-995(SCI)
3. Hsu JL, Leong PK, Ho YF, Hsu LC, Lu PH, Chen CS, Guh JH. Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair. Cancer Lett. 2012; 319:214-222.
4. Hsu JL, Ho YF, Li TK, Chen CS, Hsu LC, Guh JH. Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKC讦-independent pathway. Biochem Pharmacol. 2012; 84:59-67.
5. Wu FLL, Chen YM, Lai TS, Shen LJ, Ho YF, Lee YT, Wu MS, Lin SL, Wu KD. Does Chinese herb nephropathy account for the high incidence of end-stage renal disease in Taiwan?. Nephron Clin Pract. 2012; 120:C215-C222(SCI)
6. Ho Y-F, Lu W-C, Chen R R-L, Cheng A-L, Yeh K-H.. Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. Anti-Cancer Drugs 2011; 22:290-298(SCI)
7. Hsu JL, Pan SL, Ho YF, Hwang TL, Kung FL, Guh J-H. Costunolide induces apoptosis through nuclear calcium2+ overload and DNA damage response in human prostate cancer. J Urol. 2011; 185:1967-1974.
8. Lu PH, Yu CC, Chiang PC, Chen YC, Ho YF, Kung FL, Guh JH. Paclitaxel induces apoptosis through activation of nuclear protein kinase C-δ and subsequent activation of Golgi-associated Cdk1 in human hormone-refractory prostate cancers. J Urol. 2011; 186:2434-2441.
9. Chen L-J, Lin W-C, Lee S-J, Hsieh L-L, Lu PY, Wang S-F, Ho Y-F*. Information technology in primary care pharmacy practices. Formosan J Med 2010; 14:114-123
10. Chang WL, Chang CS, Chiang PC, Ho YF, Liu JF, Chang KW, Guh JH. 2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase. Br J Pharmacol. 2010; 160:1677-1689(SCI)
11. L.-J. Chen, W.-C. Lin, S.-J. Lee, L.-L. Hsieh1, P.Y. Lu, S.-F. Wang, Y.-F. Ho*. An analysis on the formats and contents of ambulatory prescriptions. Formosan J Med 2009; 13:449-460
12. Y.-F. Hoa, M.-H. Wu, B.-H. Cheng, Y.-W. Chen, M.-C. Shih. Lipid-mediated preferential localization of hypericin in lipid membranes. Biochim Biophys Acta 2009; 1788:1287-1295(SCI)
13. Ho Y-F*, Huang D-K, Hsueh W-C, Lai M-Y, Yu H-Y, Tsai T-H.. Effects of St. John’s wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts. Life Sciences 2009; 85:296-302(SCI)
14. 朱蓁蓁,沈麗娟,何藴芳,林慧玲. 用藥安全推動成果. 展望醫療品質雜誌. 2009; 3:23-27.
15. Chien-Yi Tung1, Wu F-L L, Lin C-C, Lin S-J, Ho Y-F*. The public’s perception towards chronic-illness refill prescriptions: community vs. hospital refill services. Formosan J Med 2008; 12:635-643(SCI)
16. Ho Y-F*, Yu H-Y, Tseng M-C, Lee S-Jn, Chan S-H.. Orphan pharmaceuticals and rare diseases under National Health Insurance. Formosan J Med 2008; 12:390-398
17. Yunn-Fang Ho, Ming-Yen Lai, Hsiu-Ying Yu, Da-Kong Huang, Wei-Cherng Hsueh, Tung-Hu Tsai, Chia-Chun Lin. Application of rat in situ single-pass intestinal perfusion in the evaluation of pre-systemic extraction of indinavir under different perfusion rates. J Formos Med Assoc 2008; 107:37-45(SCI)
18. Lin Y-S, Shen L-J, Ho Y-F, Wu F-L L. Phenytoin hypersensitivity after re-exposure in a patient with sensitivity history. Formosan J Med 2008; 12:537-542(SCI)
19. Hsiao C-J, Ho Y-F, Hsu J T-A, Chang W-L, Chen Y-C, Shen Y-Cg, Lyu P-C, Guh J-H. Mana-Hox displays anticancer activity against prostate cancers through tubulin depolymerization and DNA damage stress. Naunyn-Schmiedebergs Arch Pharmacol. 2008; 378:599-608(SCI)
20. Hsu W.-T., Shen L.-J., Ho Y.-F., Huang Z.-M., Wu F.-L. L.. Comparison of the reimbursements of pharmaceutical services in health insurance contracted pharmacies in Taiwan and Japan. Formosa J Clin Pharm 2008; 16:33-50
21. Shen L.-J., Wu F.-L. L., Ho Y.-F., Liu K C.S. Chen. Evolution of pharmacy education in Taiwan. Journal of the Korean Society of Pharmaceutical Regulatory Sciences. 2008; 3:71-77
22. Ho YF, Wu MH, Cheng BH, Chen YW, Shih MC. Lipid-mediated preferential localization of hypericin in lipid membranes. Biochim Biophys Acta. 2008; 1788:1287-1295.
23. 7. Chen Y-C, Lu P-H, Pan S-L, Teng C-M, Kuo S-C, Lin T-P, Ho Y-F, Huang Y-C, Guh J-H. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Biochem Pharmacol 2007; 74:10-19(SCI)
24. Ho Y-F*, Wu F-L L, Tsai Y-C, Chiu S-F, Lai Y-H, Ho F-H, Lin F-J.. The cognition of chronic-disease refill prescriptions of the outpatients. Formosan J Med 2006; 10:578-585
25. Chen W-H, Wu F-L L, Chou H, Chen C-N, Chen C-T, Ho Y-F, Chang S-C, Chen Y-H. Evaluation of the use of vancomycin and teicoplanin in a medical center. Formosan J Med 2006; 10:28-41
26. Ho Y-F; Wu R-S; Wu F-L L; Yang H-Y; Suen M-P; Chen W-H; Hsieh L-L; Huang C-Y; and Chen Y-H.. Establishment of a web-based pharmacy reporting system for in-patient prescribing errors.. Formosan J Med 2005; 9:439-447
27. Ho Y-F, Lai Y-H, Lin F-J, Gau M-H, Chen M-T, Chen C-H, Tzou H-Y, Lin J-T, Chen Y-H. An innovative model for releasing outpatient prescriptions from a community hospital. Formosan J Med 2003; 7(3):326-336
28. Huang S-H, Lin H-N, Wu F-L L, Ho Y-F*. Evaluation of pharmacist’s participation in the detection of drug-drug interactions. Formosan J Med 2003; 7(2):166-173
29. Ho Y-F, Huang S-H, Lin H-N. Detecting drug-drug interactions in medication profiles of psychiatric inpatients: a two-stage approach. Formos Med Assoc 2002; 101(4):294-297